TheEdgeResearch
Home / Stocks / GCTK

GlucoTrack, Inc. (GCTK)

NASDAQ Healthcare Medical - Instruments & Supplies
$0.38 ▲ +3.32%
Market Cap
$3.0M
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Beta
0.66
52-Wk Range
0.25-14.14
CEO
Erik Emerson
Country
US
Currency
USD

GlucoTrack, Inc. operates in the Medical - Instruments & Supplies industry of the Healthcare sector, headquartered in Rutherford, NJ, US. The stock last traded at $0.38, up 3.32% on the session, giving a market capitalisation of $3.0M. On trailing twelve-month figures it carries a trailing P/E of -0.02, a net margin of 0.0%. Its beta of 0.66 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.02
Price / Sales
0.00
Price / Book
-0.74
EV / EBITDA
0.06
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
Debt / equity
-0.03
Current ratio
0.85
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
15
IPO date
2013-04-25
Headquarters
Rutherford, NJ, US
About GlucoTrack, Inc.

Based in Or Yehuda, Israel, GlucoTrack, Inc. is a medical technology company focused on innovating, developing, and bringing to market non-invasive glucose monitoring systems. Their primary offering, the GlucoTrack device, enables individuals with diabetes or pre-diabetes to painlessly check their blood glucose levels. This technology is available to customers both in Israel and across the globe. The company, founded in 2001, operated under the name Integrity Applications, Inc. until it officially rebranded to GlucoTrack, Inc. in November 2021.

Comparable companies

GlucoTrack, Inc. is most often compared with the following Healthcare names:

AKANBBLGBGMSDHAIHSCSINMNAOVNDRARDHLVERO
More research on GCTK
GCTK technical analysis GCTK TheEdge Score Compare against peers
Open full interactive analysis & DCF →